Treatment response classes in major depressive disorder identified by model-based clustering and validated by clinical prediction models.


Journal

Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664

Informations de publication

Date de publication:
05 08 2019
Historique:
received: 29 11 2018
accepted: 07 07 2019
revised: 16 06 2019
entrez: 7 8 2019
pubmed: 7 8 2019
medline: 29 2 2020
Statut: epublish

Résumé

The identification of generalizable treatment response classes (TRC[s]) in major depressive disorder (MDD) would facilitate comparisons across studies and the development of treatment prediction algorithms. Here, we investigated whether such stable TRCs can be identified and predicted by clinical baseline items. We analyzed data from an observational MDD cohort (Munich Antidepressant Response Signature [MARS] study, N = 1017), treated individually by psychopharmacological and psychotherapeutic means, and a multicenter, partially randomized clinical/pharmacogenomic study (Genome-based Therapeutic Drugs for Depression [GENDEP], N = 809). Symptoms were evaluated up to week 16 (or discharge) in MARS and week 12 in GENDEP. Clustering was performed on 809 MARS patients (discovery sample) using a mixed model with the integrated completed likelihood criterion for the assessment of cluster stability, and validated through a distinct MARS validation sample and GENDEP. A random forest algorithm was used to identify prediction patterns based on 50 clinical baseline items. From the clustering of the MARS discovery sample, seven TRCs emerged ranging from fast and complete response (average 4.9 weeks until discharge, 94% remitted patients) to slow and incomplete response (10% remitted patients at week 16). These proved stable representations of treatment response dynamics in both the MARS and the GENDEP validation sample. TRCs were strongly associated with established response markers, particularly the rate of remitted patients at discharge. TRCs were predictable from clinical items, particularly personality items, life events, episode duration, and specific psychopathological features. Prediction accuracy improved significantly when cluster-derived slopes were modelled instead of individual slopes. In conclusion, model-based clustering identified distinct and clinically meaningful treatment response classes in MDD that proved robust with regard to capturing response profiles of differently designed studies. Response classes were predictable from clinical baseline characteristics. Conceptually, model-based clustering is translatable to any outcome measure and could advance the large-scale integration of studies on treatment efficacy or the neurobiology of treatment response.

Identifiants

pubmed: 31383853
doi: 10.1038/s41398-019-0524-4
pii: 10.1038/s41398-019-0524-4
pmc: PMC6683145
doi:

Substances chimiques

Antidepressive Agents 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

187

Références

Psychol Med. 2004 Oct;34(7):1299-308
pubmed: 15697056
Eur Arch Psychiatry Neurol Sci. 1985;234(6):417-22
pubmed: 4029226
J Affect Disord. 2009 Jun;115(3):439-49
pubmed: 19027961
Am J Geriatr Psychiatry. 2014 Feb;22(2):167-76
pubmed: 23567441
Am J Psychiatry. 2010 May;167(5):555-64
pubmed: 20360315
Dialogues Clin Neurosci. 2008;10(4):453-60
pubmed: 19170402
Bioinformatics. 2010 May 15;26(10):1340-7
pubmed: 20385727
Prim Care Companion CNS Disord. 2016 Sep 1;18(5):
pubmed: 27835721
PLoS One. 2017 Sep 21;12(9):e0185119
pubmed: 28934289
Am J Psychiatry. 2000 Jun;157(6):896-903
pubmed: 10831468
Psychol Med. 2014 Nov;44(15):3289-302
pubmed: 25066141
J Affect Disord. 2015 Jul 1;179:38-46
pubmed: 25845748
Eur Neuropsychopharmacol. 1999 Jan;9(1-2):83-91
pubmed: 10082232
Arch Gen Psychiatry. 1987 Jun;44(6):573-88
pubmed: 3579504
PLoS One. 2015 Jul 15;10(7):e0132765
pubmed: 26177365
Eur Neuropsychopharmacol. 2013 Nov;23(11):1503-15
pubmed: 23920122
PLoS One. 2012;7(10):e48200
pubmed: 23110213
Psychiatry Res. 2018 Sep;267:480-489
pubmed: 29980128
J Psychiatr Res. 2001 Mar-Apr;35(2):83-94
pubmed: 11377437
Mol Psychiatry. 2017 Jun;22(6):900-909
pubmed: 27137745
Lancet Psychiatry. 2016 Mar;3(3):243-50
pubmed: 26803397
J Clin Psychiatry. 2003 Apr;64(4):413-20
pubmed: 12716243
Am J Geriatr Psychiatry. 2009 May;17(5):387-96
pubmed: 19390296
Psychol Med. 2010 Jan;40(1):41-50
pubmed: 19460188
Psychiatry Res. 2009 May 15;167(1-2):115-22
pubmed: 19346004
Yonsei Med J. 2014 Nov;55(6):1712-20
pubmed: 25323911
J Clin Psychiatry. 2007;68 Suppl 8:4-10
pubmed: 17640152
Psychol Bull. 2010 Jul;136(4):576-600
pubmed: 20565169
J Clin Psychiatry. 2012 Jul;73(7):967-76
pubmed: 22687487
Biol Psychiatry. 2007 Aug 15;62(4):321-6
pubmed: 17241618
Chronic Stress (Thousand Oaks). 2017 Jan-Dec;1:
pubmed: 28856337
PLoS One. 2018 Jun 7;13(6):e0197268
pubmed: 29879133
JAMA Psychiatry. 2017 May 1;74(5):528-534
pubmed: 28355471
Psychol Med. 2008 Feb;38(2):289-300
pubmed: 17922940
Depress Anxiety. 2018 Oct;35(10):992-1000
pubmed: 30260539
Anxiety Stress Coping. 2010 Jul;23(4):363-81
pubmed: 19890753
Hum Brain Mapp. 2014 Apr;35(4):1630-41
pubmed: 23616377
J Int Neuropsychol Soc. 2017 Aug;23(7):584-593
pubmed: 28762320
Am J Psychiatry. 2014 Dec 1;171(12):1278-86
pubmed: 25017001
Transl Psychiatry. 2017 May 2;7(5):e1116
pubmed: 28463239
J Clin Psychopharmacol. 2015 Dec;35(6):706-10
pubmed: 26474010
BMC Med. 2012 Dec 04;10:156
pubmed: 23210727
Am J Psychiatry. 1998 Jun;155(6):795-9
pubmed: 9619152
Transl Psychiatry. 2013 Sep 03;3:e300
pubmed: 24002086
Am J Psychiatry. 2007 Oct;164(10):1539-46
pubmed: 17898345
J Psychiatr Res. 2009 Jan;43(3):215-29
pubmed: 18586274
J Clin Psychiatry. 2011 Nov;72(11):1478-84
pubmed: 22127194
CNS Neurosci Ther. 2010 Oct;16(5):322-5
pubmed: 19769599
Depress Anxiety. 2018 Feb;35(2):148-159
pubmed: 29228458
J Consult Clin Psychol. 2009 Dec;77(6):1067-77
pubmed: 19968383
Can J Psychiatry. 2012 Dec;57(12):782-8
pubmed: 23228238
Depress Anxiety. 2010;27(1):19-26
pubmed: 19798766
J Neuroimaging. 2011 Oct;21(4):375-82
pubmed: 20977527
J Affect Disord. 2014 Jul;163:81-7
pubmed: 24836092
J Nerv Ment Dis. 2004 Sep;192(9):595-601
pubmed: 15348975
Br J Psychiatry. 2009 Mar;194(3):252-9
pubmed: 19252156
J Affect Disord. 2008 Nov;111(1):67-73
pubmed: 18384882
Eur Neuropsychopharmacol. 2017 Oct;27(10):977-986
pubmed: 28870407
J Affect Disord. 2009 Apr;114(1-3):243-53
pubmed: 18849079
Biol Psychiatry. 2007 Jul 1;62(1):47-54
pubmed: 17123470
J Clin Psychiatry. 2015 Jun;76(6):e802-8
pubmed: 26132689
J Clin Psychiatry. 2008 Aug;69(8):1246-56
pubmed: 18681756

Auteurs

Riya Paul (R)

Max Planck Institute of Psychiatry, Munich, Germany.

Till F M Andlauer (TFM)

Max Planck Institute of Psychiatry, Munich, Germany.
Department of Neurology, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany.

Darina Czamara (D)

Max Planck Institute of Psychiatry, Munich, Germany.

David Hoehn (D)

Max Planck Institute of Psychiatry, Munich, Germany.

Susanne Lucae (S)

Max Planck Institute of Psychiatry, Munich, Germany.

Benno Pütz (B)

Max Planck Institute of Psychiatry, Munich, Germany.

Cathryn M Lewis (CM)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, United Kingdom.
Department of Medical and Molecular Genetics, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.

Rudolf Uher (R)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, United Kingdom.
Department of Pathology and Department of Psychiatry, Dalhousie University, Halifax, NS, Canada.

Bertram Müller-Myhsok (B)

Max Planck Institute of Psychiatry, Munich, Germany. bmm@psych.mpg.de.
Munich Cluster of Systems Biology, SyNergy, Germany. bmm@psych.mpg.de.
Institute of Translational Medicine, University of Liverpool, Liverpool, UK. bmm@psych.mpg.de.

Marcus Ising (M)

Max Planck Institute of Psychiatry, Munich, Germany.

Philipp G Sämann (PG)

Max Planck Institute of Psychiatry, Munich, Germany. saemann@psych.mpg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH